Used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with a specific mutation in the IDH2 gene. It works by inhibiting the mutant IDH2 enzyme, which helps restore normal differentiation of blood cells. This targeted therapy allows cancerous cells to mature into normal functioning blood cells rather than accumulating as immature blasts. Enasidenib is taken orally and offers a non-chemotherapy option for patients who may not tolerate intensive treatments. It is often considered when other therapies have failed, providing a valuable option in personalized cancer treatment.